The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics
Abstract
Thiopurine methyltransferase catalyzes the S-methylation of azathioprine (AZA), 6-mercapto-purine (6-MP) and thioguanine, medications widely used to treat malignancies, rheumatic diseases, dermatologic conditions, inflammatory bowel disease and solid organ transplant rejection. TPMT activity exhibits a genetic polymorphism in 10% of Caucasians, with 1/300 individuals having complete deficiency. Patients with intermediate or deficient TPMT activity are at risk for excessive toxicity, including fatal myelosuppression, after receiving standard doses of thiopurine medications. The molecular basis for low TPMT activity has been elucidated, leading to the development of assays for the three signature mutations, which account for the majority of mutant alleles. TPMT genotype is correlated with erythrocyte and leukemia blast cell TPMT activity and associated with a risk of toxicity after thiopurine therapy. Recent studies defined target starting doses for mercaptopurine based on TPMT genotypes. This polymorphism is one of the best models for the translation of genomic information to guide patient therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weinshilboum, R. M., & Sladek, S. L. (1980) · PubMed · Cited by 1,195
Dubinsky, M. C., Lamothe, S., Yang, H. Y., Targan, S. R., Sinnett, D., Théorêt, Y., & Seidman, E. G. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70140-5 · Cited by 996
Yates, C. R., Krynetski, E. Y., Loennechen, T., Fessing, M. Y., Tai, H.-L., Pui, C.-H., Relling, M. V., & Evans, W. E. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-8-199704150-00003 · Cited by 756
Relling, M. V., Hancock, M. L., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Krynetski, E. Y., Pui, C.-H., & Evans, W. E. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.23.2001 · Cited by 733
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
Lennard, L., Lilleyman, J. S., Van Loon, J., & Weinshilboum, R. M. (1990) · The Lancet · doi:10.1016/0140-6736(90)91745-v · Cited by 651
Colombel, J., Ferrari, N., Debuysere, H., Marteau, P., Gendre, J., Bonaz, B., Soulé, J.-C., Modigliani, R., Touze, Y., Catala, P., et al. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70354-4 · Cited by 619
Lennard, L., Van Loon, J. A., & Weinshilboum, R. M. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.119 · Cited by 593
McLeod, H., Krynetski, E., Relling, M., & Evans, W. (2000) · Leukemia · doi:10.1038/sj.leu.2401723 · Cited by 437
Self-citationHigh incidence of secondary brain tumours after radiotherapy and antimetabolites
Relling, M. V., Rubnitz, J. E., Rivera, G. K., Boyett, J. M., Hancock, M. L., Felix, C. A., Kun, L. E., Walter, A. W., Evans, W. E., & Pui, C.-H. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11079-6 · Cited by 411
Evans, W. E., Hon, Y. Y., Bomgaars, L., Coutre, S., Holdsworth, M., Janco, R., Kalwinsky, D., Keller, F., Khatib, Z., Margolin, J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2293 · Cited by 400
Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia
Relling, M. V., Hancock, M. L., Boyett, J. M., Pui, C.-H., & Evans, W. E. (1999) · Blood · doi:10.1182/blood.v93.9.2817 · Cited by 395
Evans, W. E., Horner, M., Chu, Y. Q., Kalwinsky, D., & Roberts, W. M. (1991) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83063-x · Cited by 392
Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms*
Otterness, D., Szumlanski, C., Lennard, L., Klemetsdal, B., Aarbakke, J., Park-Hah, J. O., Iven, H., Schmiegelow, K., Branum, E., O'Brien, J., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90152-1 · Cited by 390
Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine
Black, A. J., McLeod, H. L., Capell, H. A., Powrie, R. H., Matowe, L. K., Pritchard, S. C., Collie-Duguid, E. S. R., & Reid, D. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-9-199811010-00007 · Cited by 374
Self-citationCollie-Duguid, E. S. R., Pritchard, Powrie, Sludden, J., Collier, Li, T., & McLeod, H. L. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00006 · Cited by 368
Self-citationPharmacogenomics: Unlocking the Human Genome for Better Drug Therapy
McLeod, H. L., & Evans, W. E. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.101 · Cited by 331
Self-citationKrynetski, E. Y., Schuetz, J. D., Galpin, A. J., Pui, C. H., Relling, M. V., & Evans, W. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.4.949 · Cited by 306
Polymorphism of the thiopurine S-methyltransferase gene in African- Americans
Hon, Y. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.371 · Cited by 271
Tai, H.-L., Krynetski, E. Y., Schuetz, E. G., Yanishevski, Y., & Evans, W. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6444 · Cited by 259
Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.
Lennard, L., & Lilleyman, J. S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1816 · Cited by 244
Thiopurine methyltransferase alleles in British and Ghanaian populations
Ameyaw, M. M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.2.367 · Cited by 240
Schütz, E., Gummert, J., Mohr, F., & Oellerich, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)93028-y · Cited by 222
McLeod, H., Relling, M., Liu, Q., Pui, C., & Evans, W. (1995) · Blood · doi:10.1182/blood.v85.7.1897.bloodjournal8571897 · Cited by 218
Self-citationEtoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia
Relling, M., Yanishevski, Y., Nemec, J., Evans, W., Boyett, J., Behm, F., & Pui, C.-H. (1998) · Leukemia · doi:10.1038/sj.leu.2400928 · Cited by 188
Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells
Thomsen, J. B., Schr�der, H., Kristinsson, J., Madsen, B., Szumlanski, C. L., Weinshilboum, R. M., Andersen, J. B., & Schmiegelow, K. (1999) · Cancer · Cited by 172
Spire‐Vayron de la Moureyre, C., Debuysere, H., Mastain, B., Vinner, E., Marez, D., Lo Guidice, J., Chevalier, D., Brique, S., Motte, K., Colombel, J., et al. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702152 · Cited by 170
Chocair, P. R., Duley, J. A., Simmonds, H. A., & Cameron, J. S. (1992) · Transplantation · doi:10.1097/00007890-199205000-00016 · Cited by 169
Krynetski, E. Y., & Evans, W. E. (1999) · Pharmaceutical Research · doi:10.1023/a:1011909315614 · Cited by 136
Dervieux, T., Blanco, J. G., Krynetski, E. Y., Vanin, E. F., Roussel, M. F., & Relling, M. V. (2001) · PubMed · Cited by 136
Human kidney thiopurine methyltransferase purification and biochemical properties
Woodson, L. C., & Weinshilboum, R. M. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90582-8 · Cited by 133
Tai, H.-L., Fessing, M. Y., Bonten, E. J., Yanishevsky, Y., d’Azzo, A., Krynetski, E. Y., & Evans, W. E. (1999) · Pharmacogenetics and Genomics · doi:10.1097/01213011-199910000-00011 · Cited by 132
Thiopurine methyltransferase polymorphic tandem repeat: Genotype-phenotype correlation analysis
Li, Y. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108674 · Cited by 127
Otterness, D. M., Szumlanski, C. L., Wood, T. C., & Weinshilboum, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1004 · Cited by 125
Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case
Tavadia, S. M. B., Mydlarski, P. R., Reis, M. D., Mittmann, N., Pinkerton, P. H., Shear, N. H., & Sauder, D. N. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.103980 · Cited by 93
Naughton, M. (1999) · British journal of rheumatology · doi:10.1093/rheumatology/38.7.640 · Cited by 85
de la Moureyre, C. S., Debuysère, H., Fazio, F., Sergent, E., Bernard, C., Sabbagh, N., Marez, D., Lo‐Guidice, J., D'Halluin, J.-C., & Broly, F. (1999) · PubMed · Cited by 82
Alves, S. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117284 · Cited by 75
Segregation analysis of human red blood cell thiopurine methyltransferase activity
Vuchetich, J. P., Weinshilboum, R. M., & Price, R. A. (1995) · Genetic Epidemiology · doi:10.1002/gepi.1370120102 · Cited by 57
Cited by
Clinical pharmacology and pharmacogenetics of thiopurines
Sahasranaman, S., Howard, D., & Roy, S. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0478-6 · Cited by 405
Goldstein, D. B., Tate, S. K., & Sisodiya, S. M. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1229 · Cited by 312
Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics
JOHNSON, A., WANG, D., & SADEE, W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.001 · Cited by 97
Metadata
- Authors
- McLeod, H. L., & Siva, C.
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2002-01
- Volume
- 3
- Issue
- 1
- Pages
- 89-98
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W2076472107
- Cited by
- 296
- References
- 38
- FWCI
- 19.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.